Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Six Biotechnology Companies Added to the Index
Lenexa, KS -- December 15, 2020 -- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.
For the December meeting, the committee has added six new immunotherapy companies. They are ALX Oncology (Nasdaq: ALXO), Atara Biotherapeutics (Nasdaq: ATRA), Genmab (Nasdaq: GMAB), I-Mab Biopharma (Nasdaq, IMAB), Nkarta (Nasdaq: NKTX), and Scholar Rock (Nasdaq: SRRK).
These companies replace Adaptimmune (Nasdaq: ADAP), Cellectis (Nasdaq: CLLS), Compugen (Nasdaq: CGEN), Cue Biopharma (Nasdaq: CUE), Moderna (Nasdaq: MRNA), and NextCure (Nasdaq: NXTC).
“2020 has been a strong year for the field of immunotherapy. We are seeing advances emerge in the clinic from many new modalities including bi-specific antibodies, NK cell based therapies, and fusion proteins.” said Brad Loncar, CEO of Loncar Investments and Chairman of the index committee. “I very much look forward to following the progress of the components we have added today. ”
Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on June 15, 2021.
Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.
Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.
About the index: The Loncar Cancer Immunotherapy Index is an equal-weighted index of top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Additional information can be found at the index’s dedicated website, www.LoncarIndex.com.
Index provider: Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. It incorporates extensive research into biotech companies and technologies to develop stock market indexes that are focused on precise investment opportunities. The company is principally owned by biotech investor and analyst Brad Loncar.
Loncar Investments, LLC
Jill Tatios, 215-240-6398